SCHEDULE 13G
0001757011
XXXXXXXX
LIVE
Common Stock par value $0.0001 per share
03/31/2025
0001842295
Maze Therapeutics, Inc.
578784100
171 Oyster Point Blvd
Suite 300
South San Francisco
CA
94080
Rule 13d-1(d)
ARCH Venture Fund X, L.P.
DE
0.00
4120053.00
0.00
4120053.00
4120053.00
N
9.4
PN
ARCH Venture Fund X Overage, L.P.
DE
0.00
4120053.00
0.00
4120053.00
4120053.00
N
9.4
PN
ARCH Venture Partners X, L.P.
DE
0.00
4120053.00
0.00
4120053.00
4120053.00
N
9.4
PN
ARCH Venture Partners X Overage, L.P.
DE
0.00
4120053.00
0.00
4120053.00
4120053.00
N
9.4
PN
ARCH Venture Partners X, LLC
DE
0.00
4120053.00
0.00
4120053.00
4120053.00
N
9.4
OO
Keith Crandell
X1
0.00
4120053.00
0.00
4120053.00
4120053.00
N
9.4
IN
Kristina Burow
X1
0.00
4120053.00
0.00
4120053.00
4120053.00
N
9.4
IN
Steven Gillis
X1
0.00
4120053.00
0.00
4120053.00
4120053.00
N
9.4
IN
Robert Nelsen
X1
0.00
4120053.00
0.00
4120053.00
4120053.00
N
9.4
IN
Maze Therapeutics, Inc.
171 Oyster Point Blvd., Suite 300, South San Francisco, CA 94080
ARCH Venture Fund X, L.P. ("AVF X"); ARCH Venture Partners X, L.P. ("AVP X LP"); ARCH Venture Partners X, LLC ("AVP X LLC"); ARCH Venture Fund X Overage, L.P. ("AVF X Overage"); ARCH Venture Partners X Overage, L.P. ("AVP X Overage GP") (collectively, the "Reporting Entities" and individually, each a "Reporting Entity"); and Keith Crandell ("Crandell"), Robert Nelsen ("Nelsen"), Kristina Burow ("Burow") and Steven Gillis ("Gillis) (collectively, the "Investment Committee" and individually, each a "Committee Member"). The Reporting Entities and the Committee Members collectively are referred to as the "Reporting Persons".
8755 W. Higgins Avenue, Suite 1025, Chicago, IL 60631
Each of AVF X, AVP X LP, AVF X Overage and AVP X Overage GP, are limited partnerships organized under the laws of the State of Delaware. AVP X LLC is a limited liability company organized under the laws of the State of Delaware. Each Committee Member is a US citizen.
Y
AVF X is the record owner of 1,949,930 shares of Common Stock (the "AVF X Shares") as of March 31, 2025. AVP X LP, as the sole general partner of ARCH Venture Fund X, may be deemed to beneficially own the AVF X Shares. AVF X Overage is the record owner of 2,170,123 shares of Common Stock (the "AVF X Overage Shares"; combined with AVF X Shares, the "Record Shares") as of March 31, 2025. AVP X Overage GP, as the sole general partner of AVF X Overage, may be deemed to beneficially own the AVF X Overage Shares. AVP X LLC, as the sole general partner of AVP X LP and AVP X Overage LP, may be deemed to beneficially own the Record Shares. As Committee Members of AVP X LLC, each Committee Member may also be deemed to share the power to direct the disposition and vote of the Record Shares.
See line 11 of the cover sheets. The percentages set forth on the cover sheet for each Reporting Person is based upon 43,796,057 shares of common stock outstanding as of March 25, 2025 as reported on the Issuer's Form 10-K as filed with the Securities and Exchange Commission on March 31, 2025.
See line 5 of the cover sheets.
See line 6 of the cover sheets.
See line 7 of the cover sheets.
See line 8 of the cover sheets.
Y
Y
Y
Y
Y
Y
ARCH Venture Fund X, L.P.
ARCH Venture Partners X, L.P.
its General Partner
05/15/2025
ARCH Venture Partners X, LLC
its General Partner
05/15/2025
/s/ Mark McDonnell
* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
05/15/2025
ARCH Venture Fund X Overage, L.P.
ARCH Venture Partners X Overage, L.P.
its General Partner
05/15/2025
ARCH Venture Partners X, LLC
its General Partner
05/15/2025
/s/ Mark McDonnell
* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
05/15/2025
ARCH Venture Partners X, L.P.
ARCH Venture Partners X, LLC
its General Partner
05/15/2025
/s/ Mark McDonnell
* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
05/15/2025
ARCH Venture Partners X Overage, L.P.
ARCH Venture Partners X, LLC
its General Partner
05/15/2025
/s/ Mark McDonnell
* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
05/15/2025
ARCH Venture Partners X, LLC
/s/ Mark McDonnell
* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
05/15/2025
Keith Crandell
/s/ Mark McDonnell
* Mark McDonnell, as Attorney-in-Fact for Keith Crandell
05/15/2025
Kristina Burow
/s/ Mark McDonnell
* Mark McDonnell, as Attorney-in-Fact for Kristina Burow
05/15/2025
Steven Gillis
/s/ Mark McDonnell
* Mark McDonnell, as Attorney-in-Fact for Steven Gillis
05/15/2025
Robert Nelsen
/s/ Mark McDonnell
* Mark McDonnell, as Attorney-in-Fact for Robert Nelsen
05/15/2025
* This Schedule 13G was executed by Mark McDonnell pursuant to a Power of Attorney filed as Exhibit 24 and 24.1 to the Form 3 relating to the beneficial ownership of shares of Verve Therapeutics, Inc. by the Reporting Persons filed with the Securities Exchange Commission on June 16, 2021 and incorporated herein in its entirety by reference.